Is Sunshine Biopharma, Inc. a good investment? Sunshine Biopharma, Inc. (SBFM) is currently trading at 2.75 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.20. This relatively low multiple may signal that Sunshine Biopharma, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Sunshine Biopharma, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is 199.80.
No, it does not currently pay a dividend.
Sunshine Biopharma, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -189.00.
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 1, 2019 | 1:20 |
| April 6, 2020 | 1:20 |
| Feb. 9, 2022 | 1:100 |
| April 17, 2024 | 1:100 |
| Aug. 8, 2024 | 1:20 |
| June 1, 2026 | 1:10 |
| Oct. 26, 2026 | 1:20 |
Community Discussion